Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Conchon, Monika, Freitas, Carla Maria Boquimpani de Moura, Rego, Maria Aparecida do Carmo, Braga Junior, José Wilson Ramos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Hematologia e Hemoterapia 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520638/
https://www.ncbi.nlm.nih.gov/pubmed/23284261
http://dx.doi.org/10.5581/1516-8484.20110034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520638/
https://www.ncbi.nlm.nih.gov/pubmed/23284261
http://dx.doi.org/10.5581/1516-8484.20110034

Ejemplares similares